Thanks to the development of biochemical immunoassays for plasma insulin, it is widely believed that a diminished first-phase insulin release is the earliest detectable defect of β-cell function in individuals destined to develop T2D [16, 17, 29]. The gene discussed is INS; the disease is type 2 diabetes mellitus.